UroGen Pharma

Update in progress

URGN (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

UroGen Pharma Ltd. is a Princeton, New Jersey–based biotechnology company focused on therapies for urothelial and related cancers. It develops and commercializes RTGel, a biocompatible reverse-thermal hydrogel, and mitomycin-based products such as Jelmyto and Zusduri for non-muscle invasive bladder cancer. Lead programs UGN-103 (intravesical) and UGN-104 (pyelocalyceal) are in Phase 3, with additional Phase 1 programs. It has licensing agreements with Agenus and medac.

Company score

Sentiment: 0.51; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.02; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.50; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.21; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.20; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.35; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive